钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制  

Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits

作　　者：张欣 郭艺芳 ZHANG Xin;GUO Yifang(Hebei North University Graduate School,Zhangjiakou 075000,Hebei,China;Department of Geriatric Cardiology,Hebei General Hospital,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北北方学院研究生部,河北张家口075000 [2]河北省人民医院老年心内科,河北石家庄050051

出　　处：《心血管病学进展》2020年第9期903-906,共4页Advances in Cardiovascular Diseases

摘　　要：心血管疾病是糖尿病患者致死致残的主要原因,最近指南建议2型糖尿病合并心血管疾病的患者优先选用具有心血管保护作用的药物。钠-葡萄糖协同转运蛋白2抑制剂是一种新型降糖药,其降糖效果肯定,且被临床试验证实具有心血管保护作用。迄今为止,此类药物产生心血管获益的机制仍不清楚,笔者结合现有研究对此进行讨论。Cardiovascular disease is the main cause of death and disability in patients with diabetes mellitus.Recently,the guideline suggests that the patients with type 2 diabetes mellitus combined with cardiovascular disease should choose the drugs with cardiovascular protective effect preferentially.Sodium-glucose co-transporter 2 inhibitor is a new type of hypoglycemic drug,which has a definite hypoglycemic effect and has been proved to have cardiovascular protective effect by clinical trials.But until now,the mechanism of cardiovascular benefits of these drugs is still unclear.In this paper,the existing research is discussed.

关 键 词：心血管疾病 2型糖尿病 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R587.2[医药卫生—内分泌]